Leiomyosarcoma - Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Leiomyosarcoma - Pipeline Review, H2 2012', provides an overview of the Leiomyosarcoma therapeutic pipeline. This report provides information on the therapeutic development for Leiomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leiomyosarcoma. 'Leiomyosarcoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Reasons to buy
Keywords
Leiomyosarcoma Therapeutic Products under Development, Key Players in Leiomyosarcoma Therapeutics, Leiomyosarcoma Pipeline Overview, Leiomyosarcoma Pipeline, Leiomyosarcoma Pipeline Assessment
Summary
Global Markets Direct’s, 'Leiomyosarcoma - Pipeline Review, H2 2012', provides an overview of the Leiomyosarcoma therapeutic pipeline. This report provides information on the therapeutic development for Leiomyosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leiomyosarcoma. 'Leiomyosarcoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Leiomyosarcoma.
- A review of the Leiomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Leiomyosarcoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Leiomyosarcoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Leiomyosarcoma Therapeutic Products under Development, Key Players in Leiomyosarcoma Therapeutics, Leiomyosarcoma Pipeline Overview, Leiomyosarcoma Pipeline, Leiomyosarcoma Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Leiomyosarcoma Overview
Therapeutics Development
An Overview of Pipeline Products for Leiomyosarcoma
Leiomyosarcoma Therapeutics under Development by Companies
Leiomyosarcoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Leiomyosarcoma Therapeutics – Products under Development by Companies
Leiomyosarcoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Leiomyosarcoma Therapeutics Development
Eli Lilly and Company
Leiomyosarcoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
IMC-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Filgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Trabectedin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ixabepilone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel + Filgrastim + Pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Pegfilgrastim + Docetaxel + Doxorubicin Hydrochloride + Gemcitabine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOV110501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leiomyosarcoma Therapeutics – Drug Profile Updates
Leiomyosarcoma Therapeutics – Discontinued Products
Leiomyosarcoma Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Leiomyosarcoma, H2 2012
Products under Development for Leiomyosarcoma – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Eli Lilly and Company, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Leiomyosarcoma Therapeutics – Drug Profile Updates
Leiomyosarcoma Therapeutics – Discontinued Products
Leiomyosarcoma Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Leiomyosarcoma, H2 2012
Products under Development for Leiomyosarcoma – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Leiomyosarcoma Overview
Therapeutics Development
An Overview of Pipeline Products for Leiomyosarcoma
Leiomyosarcoma Therapeutics under Development by Companies
Leiomyosarcoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Leiomyosarcoma Therapeutics – Products under Development by Companies
Leiomyosarcoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Leiomyosarcoma Therapeutics Development
Eli Lilly and Company
Leiomyosarcoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
IMC-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Filgrastim + Docetaxel + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Trabectedin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ixabepilone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Docetaxel + Filgrastim + Pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Pegfilgrastim + Docetaxel + Doxorubicin Hydrochloride + Gemcitabine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOV110501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leiomyosarcoma Therapeutics – Drug Profile Updates
Leiomyosarcoma Therapeutics – Discontinued Products
Leiomyosarcoma Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Leiomyosarcoma, H2 2012
Products under Development for Leiomyosarcoma – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Eli Lilly and Company, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Leiomyosarcoma Therapeutics – Drug Profile Updates
Leiomyosarcoma Therapeutics – Discontinued Products
Leiomyosarcoma Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Leiomyosarcoma, H2 2012
Products under Development for Leiomyosarcoma – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012